New Ways to Treat Diffuse Large B Cell Lymphoma
Official title: From pathogenesis to new therapeutic targets in diffuse large B cell lymphoma
Funded at Columbia University Health Sciences · NIH-11158782 · Data updated 2026-11-12
This project explores the genetic differences in diffuse large B cell lymphoma to discover new treatment options for patients.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Columbia University Health Sciences NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | September 12, 2023 |
| Project end | July 31, 2030 |
| Funding year | 2025 |
| Award (this year) | $987,000 |
| NIH project number | 5R35CA210105-10 |
| Project ID | NIH-11158782 on NIH RePORTER |
Who could benefit from this research
✓Could help
This foundational research is focused on understanding the disease at a molecular level, so it is not directly recruiting patients for a clinical trial at this stage.
✕Less likely to help
Patients without diffuse large B cell lymphoma would not directly benefit from this specific research.
What this research studies
Diffuse Large B cell Lymphoma (DLBCL) can be challenging to treat for many patients, even with advanced therapies like CAR-T cells. A key reason for this difficulty is the wide variety in these tumors, which current classification methods don't fully capture. This project looks beyond the usual genetic analysis to focus on specific 'non-coding' parts of the DNA, called enhancers, which act like switches for genes. Researchers found that these enhancer regions are often highly mutated in DLBCL, and these mutations can prevent important genes from being properly controlled, potentially driving the cancer. By understanding these specific mutations, we hope to find new targets for medicines.
Why it matters
Potential benefit: If successful, this research could lead to new, more targeted treatments for diffuse large B cell lymphoma, especially for patients whose tumors are currently hard to classify or treat.
How similar studies have gone: This project builds on recent discoveries about hypermutated enhancer regions in DLBCL, suggesting a novel approach to understanding the disease's genetic complexity.
Where this research is happening
-
Columbia University Health Sciences
New York, United States Active
Researchers
- Principal investigator: Dalla-Favera, Riccardo — Columbia University Health Sciences
- Study coordinator: Dalla-Favera, Riccardo
Related research
Other NIH-funded projects on the same topics.
-
Immune Evasion by HLA-E in Diffuse Large B-Cell Lymphoma
A researcher is studying how a molecule called HLA-E helps a type of blood cancer (DLBCL) hide from the immune system, with findings that may lead to better treatments.
-
Cardioprotective treatment choices for DLBCL patients at risk of heart damage
Atrially, this study tests two heart-protecting drugs given during cancer treatment to see which best prevents heart problems in patients with diffuse large B-cell lymphoma who are at higher risk for heart damage.
-
Translating Genomics to Practice to Overcome Disparities in DLBCL
A patient-focused project aims to understand why diffuse large B-cell lymphoma outcomes differ among people and how genomic information can guide better care for diverse groups.
-
From pathogenesis to new targets for treating diffuse large B-cell lymphoma
A patient-focused look at how this research aims to uncover new genetic clues to guide targeted therapies for diffuse large B-cell lymphoma.
-
Understanding how immune features predict immunotherapy response in diffuse large B-cell lymphoma
A study to find genomic and immune markers in diffuse large B-cell lymphoma that could help predict who benefits from immunotherapies.
-
Lowering c-Myc to treat aggressive large B‑cell lymphoma
This work develops drugs that make the cancer protein c‑Myc break down, aiming to help people with aggressive large B‑cell lymphoma that overproduce c‑Myc.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.